

GLOBAL WEBINAR

SGLT2 Inhibition in Heart Failure: NEW UPDATES

SATURDAY, JANUARY 28TH, 2023

7:00 am PST / 10:00 am EST / 3:00 pm GMT / 8:30 pm IST

FACULTY



Harriette G. C. Van Spall,

MD, MPH, FRCPC

PROGRAM CHAIR

Population Health Research Institute and
Research Institute of St. Joe's;
Associate Professor of Medicine, McMaster University;
Hamilton, ON, Canada



Nandini Gupta,

MD, FRCPC

PROGRAM CO-CHAIR

Mackenzie Health,
Richmond Hill, ON, Canada



Pardeep S. Jhund,

BSc, MSc, PhD, MBChB,

Queen Elizabeth University Hospital;
Professor of Cardiology and Epidemiology,
University of Glasgow;
Glasgow, Scotland



John J. V. McMurray,

OBE, BSc (Hons), MB ChB (Hons), MD, FRCP,

FESC, FACC, FAHA, FRSE, FMedSci

Queen Elizabeth University Hospital;
Professor of Medical Cardiology,
University of Glasgow;
Glasgow, Scotland



Eileen O'Meara,

MD, FRCPC

Montreal Heart Institute;
Professor of Medicine, Université de Montréal;
Montreal, QC, Canada



Scott D. Solomon,

MD, FACC, FHFA

Brigham and Women's Hospital;
Professor of Medicine, Harvard Medical School;
Boston, MA, USA



Muthiah Vaduganathan,

MD, MPH, FACC

Brigham and Women's Hospital;
Instructor in Medicine, Harvard Medical School;
Boston, MA, USA



Orly Vardeny,

PharmD, MS, BCPS, FHFA

Minneapolis VA Center for Care Delivery and
Outcomes Research;
Associate Professor of Medicine,
University of Minnesota Medical School;
Minneapolis, MN, USA



Subodh Verma,

MD, PhD, FRCSC, FAHA

St. Michael's Hospital;
Professor of Surgery and Pharmacology &
Toxicology, University of Toronto;
Toronto, ON, Canada



Xiaowen "Wendy" Wang,

MD

Brigham and Women's Hospital;
Cardiovascular Medicine Fellow,
Harvard Medical School;
Boston, MA, USA

AGENDA

- | | |
|---------------|---|
| 00:00 - 00:05 | Welcome and Opening Remarks
Harriette Van Spall |
| 00:05 - 00:20 | Plenary #1: Do the kidneys hold clues to the HF benefits of SGLT2 inhibitors?
John McMurray |
| 00:20 - 00:30 | SGLT2 inhibition in the elderly and frail patients
Pardeep Jhund |
| 00:30 - 00:40 | Gender differences in outcomes with SGLT2 inhibitors
Xiaowen "Wendy" Wang |
| 00:40 - 00:50 | Efficacy and safety of SGLT2 inhibitors in Black patients
Subodh Verma |
| 00:50 - 01:10 | Q&A/Panel Discussion |
| 01:10 - 01:20 | Break |
| 01:20 - 01:30 | SGLT2 inhibition in patients with improved EF
Orly Vardeny |
| 01:30 - 01:40 | SGLT2 inhibition with MRAs and ARNIs
Muthiah Vaduganathan |
| 01:40 - 01:50 | Does NT-proBNP affect the efficacy of SGLT2 inhibitors?
Eileen O'Meara |
| 01:50 - 02:05 | Plenary #2: Does EF still matter in HF management?
Scott Solomon |
| 02:05 - 02:25 | Q&A/Panel Discussion |
| 02:25 - 02:30 | Closing Remarks
Nandini Gupta |

Learning Objectives

1. To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
2. To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
3. To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
4. To recognize the prognostic value of NT-proBNP in SGLT2 inhibition
5. To assess the merit of ejection fraction in heart failure care

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists-Association Canadienne des pathologistes. You may claim a maximum of 2.25 hours (credits are automatically calculated). Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credit to AMA credit can be found at <http://www.ama-assn.org/go/internationalcme>. Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group.

To register go to:
www.SGLT2iandHF.com